Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 26 | 2023 | 4823 | 3.870 |
Why?
|
Terminal Care | 25 | 2023 | 1688 | 3.010 |
Why?
|
Hospice Care | 14 | 2023 | 671 | 1.730 |
Why?
|
Genital Neoplasms, Female | 5 | 2023 | 516 | 1.600 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 663 | 1.160 |
Why?
|
Neoplasms | 30 | 2023 | 21596 | 1.100 |
Why?
|
Fatigue | 4 | 2023 | 1526 | 1.060 |
Why?
|
Femoracetabular Impingement | 2 | 2020 | 189 | 1.050 |
Why?
|
Patient Preference | 6 | 2022 | 886 | 1.010 |
Why?
|
Endometrial Neoplasms | 5 | 2022 | 1351 | 0.950 |
Why?
|
Caregivers | 13 | 2023 | 2074 | 0.950 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2018 | 484 | 0.940 |
Why?
|
Quality of Life | 22 | 2023 | 12730 | 0.920 |
Why?
|
Exercise Therapy | 3 | 2020 | 904 | 0.850 |
Why?
|
Terminally Ill | 6 | 2016 | 238 | 0.840 |
Why?
|
Analgesics, Opioid | 4 | 2023 | 3667 | 0.840 |
Why?
|
Rosa | 1 | 2021 | 8 | 0.830 |
Why?
|
Uterine Cervical Neoplasms | 7 | 2021 | 2011 | 0.830 |
Why?
|
Neoadjuvant Therapy | 6 | 2018 | 2721 | 0.810 |
Why?
|
Medical History Taking | 2 | 2021 | 783 | 0.740 |
Why?
|
Hip | 1 | 2021 | 257 | 0.700 |
Why?
|
Antineoplastic Agents | 8 | 2022 | 13655 | 0.700 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2022 | 9185 | 0.690 |
Why?
|
Sexual Dysfunctions, Psychological | 2 | 2019 | 187 | 0.690 |
Why?
|
Hospices | 4 | 2017 | 264 | 0.670 |
Why?
|
Platinum Compounds | 1 | 2019 | 96 | 0.670 |
Why?
|
Genetic Testing | 2 | 2022 | 3439 | 0.640 |
Why?
|
Telemedicine | 4 | 2023 | 2853 | 0.610 |
Why?
|
Palliative Care | 10 | 2023 | 3478 | 0.600 |
Why?
|
Genetic Counseling | 1 | 2020 | 600 | 0.580 |
Why?
|
Arthralgia | 1 | 2021 | 456 | 0.580 |
Why?
|
Allied Health Personnel | 1 | 2018 | 162 | 0.560 |
Why?
|
Insurance, Health | 5 | 2022 | 2493 | 0.530 |
Why?
|
Cost of Illness | 2 | 2022 | 1852 | 0.520 |
Why?
|
Bereavement | 3 | 2022 | 273 | 0.510 |
Why?
|
Sports | 1 | 2021 | 686 | 0.510 |
Why?
|
Female | 84 | 2023 | 379592 | 0.500 |
Why?
|
SEER Program | 7 | 2021 | 1507 | 0.490 |
Why?
|
Death | 5 | 2023 | 675 | 0.490 |
Why?
|
CA-125 Antigen | 1 | 2016 | 279 | 0.480 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2017 | 357 | 0.480 |
Why?
|
Humans | 109 | 2023 | 742088 | 0.470 |
Why?
|
Insurance Coverage | 4 | 2021 | 1895 | 0.460 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2017 | 780 | 0.450 |
Why?
|
Exercise | 2 | 2021 | 5611 | 0.450 |
Why?
|
Patient Compliance | 2 | 2020 | 2680 | 0.440 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2019 | 3471 | 0.430 |
Why?
|
Advance Care Planning | 6 | 2019 | 660 | 0.430 |
Why?
|
Research Support as Topic | 1 | 2017 | 704 | 0.430 |
Why?
|
Aged | 45 | 2023 | 162944 | 0.420 |
Why?
|
Workload | 1 | 2018 | 849 | 0.410 |
Why?
|
Acculturation | 1 | 2013 | 181 | 0.400 |
Why?
|
Athletic Injuries | 1 | 2021 | 1153 | 0.390 |
Why?
|
Physical Therapy Modalities | 2 | 2016 | 547 | 0.390 |
Why?
|
Public Health Administration | 1 | 2013 | 239 | 0.390 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2021 | 1208 | 0.380 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7276 | 0.380 |
Why?
|
Middle Aged | 46 | 2023 | 213127 | 0.380 |
Why?
|
Pilot Projects | 5 | 2023 | 8297 | 0.370 |
Why?
|
Physician-Patient Relations | 6 | 2021 | 3215 | 0.350 |
Why?
|
Health Services Accessibility | 3 | 2021 | 5133 | 0.350 |
Why?
|
Reoperation | 1 | 2019 | 4200 | 0.340 |
Why?
|
Medical Oncology | 6 | 2023 | 2235 | 0.340 |
Why?
|
Research | 1 | 2018 | 1999 | 0.340 |
Why?
|
Burnout, Professional | 1 | 2018 | 690 | 0.340 |
Why?
|
United States | 25 | 2023 | 69693 | 0.320 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2275 | 0.320 |
Why?
|
Attitude to Death | 6 | 2011 | 382 | 0.320 |
Why?
|
Family | 2 | 2016 | 3144 | 0.320 |
Why?
|
Oncogenes | 1 | 2013 | 1263 | 0.300 |
Why?
|
Circumcision, Male | 1 | 2008 | 150 | 0.300 |
Why?
|
Medicare | 9 | 2023 | 6532 | 0.300 |
Why?
|
Adult | 32 | 2023 | 213712 | 0.290 |
Why?
|
International Cooperation | 1 | 2013 | 1421 | 0.290 |
Why?
|
Neoplasm Staging | 10 | 2021 | 11001 | 0.280 |
Why?
|
Osteoarthritis, Hip | 1 | 2011 | 412 | 0.280 |
Why?
|
Feasibility Studies | 3 | 2022 | 5062 | 0.280 |
Why?
|
Tobacco Industry | 1 | 2007 | 126 | 0.270 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2005 | 103 | 0.260 |
Why?
|
Antitrust Laws | 1 | 2004 | 7 | 0.260 |
Why?
|
Marketing | 1 | 2007 | 208 | 0.250 |
Why?
|
Abortion, Legal | 1 | 2006 | 116 | 0.250 |
Why?
|
Nursing Care | 1 | 2005 | 74 | 0.250 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2006 | 224 | 0.250 |
Why?
|
Medication Systems, Hospital | 1 | 2005 | 158 | 0.250 |
Why?
|
Biomedical Research | 2 | 2018 | 3306 | 0.250 |
Why?
|
Psychotherapy, Group | 2 | 2019 | 407 | 0.250 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 2231 | 0.250 |
Why?
|
Prospective Studies | 13 | 2021 | 53187 | 0.240 |
Why?
|
Qualitative Research | 5 | 2022 | 2680 | 0.240 |
Why?
|
Life Expectancy | 4 | 2020 | 1183 | 0.230 |
Why?
|
Aged, 80 and over | 13 | 2022 | 57683 | 0.230 |
Why?
|
Communication | 5 | 2023 | 3728 | 0.230 |
Why?
|
Relief Work | 1 | 2004 | 137 | 0.220 |
Why?
|
Medically Uninsured | 2 | 2021 | 852 | 0.220 |
Why?
|
Personnel Selection | 1 | 2004 | 189 | 0.210 |
Why?
|
Early Detection of Cancer | 3 | 2023 | 3070 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2016 | 839 | 0.210 |
Why?
|
Stress, Psychological | 1 | 2017 | 4229 | 0.210 |
Why?
|
Salaries and Fringe Benefits | 1 | 2004 | 264 | 0.210 |
Why?
|
Hip Joint | 2 | 2020 | 1002 | 0.200 |
Why?
|
Drug Prescriptions | 2 | 2021 | 1636 | 0.200 |
Why?
|
Pyrimidinones | 2 | 2021 | 370 | 0.200 |
Why?
|
Adult Children | 1 | 2022 | 99 | 0.200 |
Why?
|
Patient Satisfaction | 4 | 2018 | 3391 | 0.200 |
Why?
|
Papillomaviridae | 2 | 2013 | 1118 | 0.200 |
Why?
|
HIV Infections | 5 | 2015 | 16678 | 0.190 |
Why?
|
Quality of Health Care | 2 | 2016 | 4369 | 0.190 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 6754 | 0.190 |
Why?
|
Adenocarcinoma | 3 | 2018 | 6347 | 0.190 |
Why?
|
Mental Health | 3 | 2010 | 2997 | 0.190 |
Why?
|
Male | 39 | 2023 | 349538 | 0.190 |
Why?
|
Self Care | 1 | 2006 | 786 | 0.190 |
Why?
|
Survival Rate | 7 | 2021 | 12773 | 0.180 |
Why?
|
Viral Vaccines | 1 | 2006 | 636 | 0.180 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 424 | 0.180 |
Why?
|
Nurse's Role | 1 | 2022 | 209 | 0.180 |
Why?
|
Ovarian Cysts | 1 | 2020 | 115 | 0.180 |
Why?
|
Adaptation, Psychological | 5 | 2011 | 2575 | 0.180 |
Why?
|
Public Health | 2 | 2017 | 2594 | 0.180 |
Why?
|
Delivery of Health Care | 1 | 2018 | 5304 | 0.170 |
Why?
|
Physicians | 1 | 2018 | 4554 | 0.170 |
Why?
|
Shoulder | 1 | 2021 | 299 | 0.170 |
Why?
|
Spouses | 1 | 2022 | 284 | 0.170 |
Why?
|
Combined Modality Therapy | 4 | 2021 | 8621 | 0.170 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 24913 | 0.170 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12344 | 0.170 |
Why?
|
Spirituality | 4 | 2011 | 405 | 0.170 |
Why?
|
Medication Errors | 1 | 2005 | 797 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 11472 | 0.170 |
Why?
|
Medicare Part D | 1 | 2023 | 326 | 0.170 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2021 | 336 | 0.160 |
Why?
|
Resistance Training | 1 | 2020 | 164 | 0.160 |
Why?
|
Patient-Centered Care | 3 | 2023 | 1436 | 0.160 |
Why?
|
Lung Neoplasms | 3 | 2023 | 13019 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 4029 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 438 | 0.160 |
Why?
|
Yoga | 1 | 2021 | 253 | 0.160 |
Why?
|
Leadership | 2 | 2018 | 1357 | 0.160 |
Why?
|
Colorado | 1 | 2018 | 162 | 0.160 |
Why?
|
Health Services Administration | 1 | 2018 | 64 | 0.150 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2020 | 324 | 0.150 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1372 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 9941 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 1097 | 0.150 |
Why?
|
Obesity | 3 | 2017 | 12705 | 0.150 |
Why?
|
Patients | 1 | 2023 | 892 | 0.150 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2021 | 450 | 0.150 |
Why?
|
Goals | 1 | 2022 | 705 | 0.140 |
Why?
|
Young Adult | 8 | 2020 | 56350 | 0.140 |
Why?
|
Psychotherapy, Brief | 1 | 2017 | 114 | 0.140 |
Why?
|
Drug Therapy | 1 | 2019 | 497 | 0.140 |
Why?
|
Health Expenditures | 3 | 2019 | 2346 | 0.140 |
Why?
|
Time Factors | 6 | 2021 | 40054 | 0.140 |
Why?
|
Intensive Care Units | 3 | 2016 | 3679 | 0.140 |
Why?
|
Health Policy | 1 | 2008 | 2657 | 0.140 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2021 | 700 | 0.130 |
Why?
|
Medicaid | 2 | 2021 | 2716 | 0.130 |
Why?
|
Papillomavirus Infections | 2 | 2013 | 1585 | 0.130 |
Why?
|
Budgets | 1 | 2017 | 227 | 0.130 |
Why?
|
Propensity Score | 2 | 2019 | 1771 | 0.130 |
Why?
|
Self Efficacy | 1 | 2019 | 610 | 0.130 |
Why?
|
Leukemia | 1 | 2023 | 1507 | 0.130 |
Why?
|
Drug Utilization | 1 | 2021 | 1181 | 0.130 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 424 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2019 | 623 | 0.130 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 2271 | 0.120 |
Why?
|
Disease-Free Survival | 3 | 2020 | 6891 | 0.120 |
Why?
|
Natural Language Processing | 2 | 2019 | 1035 | 0.120 |
Why?
|
Efficiency | 1 | 2018 | 462 | 0.120 |
Why?
|
Cohort Studies | 9 | 2021 | 40450 | 0.120 |
Why?
|
South Africa | 3 | 2015 | 1728 | 0.120 |
Why?
|
Science | 1 | 2017 | 241 | 0.120 |
Why?
|
Telephone | 1 | 2017 | 617 | 0.120 |
Why?
|
Job Satisfaction | 1 | 2018 | 535 | 0.120 |
Why?
|
Hospitalization | 3 | 2022 | 10232 | 0.120 |
Why?
|
Doxorubicin | 1 | 2020 | 2215 | 0.120 |
Why?
|
Athletes | 1 | 2021 | 1092 | 0.120 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 681 | 0.120 |
Why?
|
Developing Countries | 1 | 2006 | 2789 | 0.110 |
Why?
|
Pyrazoles | 2 | 2021 | 1970 | 0.110 |
Why?
|
Documentation | 1 | 2019 | 865 | 0.110 |
Why?
|
Efficiency, Organizational | 1 | 2018 | 695 | 0.110 |
Why?
|
Withholding Treatment | 2 | 2015 | 598 | 0.110 |
Why?
|
Genes, erbB-1 | 1 | 2013 | 161 | 0.110 |
Why?
|
Mutation | 3 | 2013 | 29717 | 0.110 |
Why?
|
Health Maintenance Organizations | 1 | 2015 | 642 | 0.110 |
Why?
|
Delphi Technique | 1 | 2015 | 778 | 0.110 |
Why?
|
MutS Homolog 2 Protein | 1 | 2012 | 200 | 0.110 |
Why?
|
Critical Care | 2 | 2016 | 2640 | 0.100 |
Why?
|
Single-Blind Method | 1 | 2016 | 1589 | 0.100 |
Why?
|
Prognosis | 5 | 2023 | 29010 | 0.100 |
Why?
|
Treatment Refusal | 1 | 2015 | 416 | 0.100 |
Why?
|
Muscle Strength | 1 | 2016 | 586 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.100 |
Why?
|
Cancer Care Facilities | 2 | 2013 | 401 | 0.100 |
Why?
|
Uterine Neoplasms | 1 | 2021 | 1513 | 0.100 |
Why?
|
Cell Cycle Proteins | 2 | 2021 | 3444 | 0.100 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 484 | 0.100 |
Why?
|
Motivation | 1 | 2021 | 1968 | 0.100 |
Why?
|
Survival Analysis | 5 | 2019 | 10248 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5171 | 0.100 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 724 | 0.090 |
Why?
|
Evidence-Based Practice | 1 | 2015 | 500 | 0.090 |
Why?
|
Religion and Medicine | 2 | 2009 | 163 | 0.090 |
Why?
|
Fee-for-Service Plans | 1 | 2016 | 694 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2021 | 1831 | 0.090 |
Why?
|
Meningeal Neoplasms | 1 | 2019 | 1241 | 0.090 |
Why?
|
Fertility | 1 | 2015 | 770 | 0.090 |
Why?
|
Anxiety Disorders | 2 | 2020 | 2684 | 0.090 |
Why?
|
Mass Screening | 1 | 2006 | 5238 | 0.090 |
Why?
|
Smoking | 1 | 2007 | 8969 | 0.090 |
Why?
|
Vagina | 1 | 2015 | 825 | 0.090 |
Why?
|
Program Evaluation | 1 | 2018 | 2485 | 0.090 |
Why?
|
Phthalazines | 2 | 2022 | 361 | 0.090 |
Why?
|
Adolescent | 7 | 2019 | 85649 | 0.090 |
Why?
|
Emergency Service, Hospital | 2 | 2021 | 7645 | 0.090 |
Why?
|
Faculty, Medical | 1 | 2018 | 1182 | 0.090 |
Why?
|
Information Dissemination | 1 | 2018 | 1100 | 0.090 |
Why?
|
Spiritual Therapies | 1 | 2009 | 58 | 0.090 |
Why?
|
Advance Directives | 1 | 2011 | 245 | 0.080 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 890 | 0.080 |
Why?
|
Radiation Oncology | 1 | 2015 | 554 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.080 |
Why?
|
Disclosure | 1 | 2015 | 736 | 0.080 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1577 | 0.080 |
Why?
|
Health Resources | 1 | 2015 | 911 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 600 | 0.080 |
Why?
|
Attitude to Health | 2 | 2015 | 2051 | 0.080 |
Why?
|
Attitude of Health Personnel | 2 | 2020 | 3839 | 0.080 |
Why?
|
Patient Selection | 1 | 2020 | 4214 | 0.080 |
Why?
|
Length of Stay | 2 | 2014 | 6294 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2013 | 4187 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 4 | 2019 | 6534 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2020 | 3527 | 0.080 |
Why?
|
Brachytherapy | 1 | 2015 | 1246 | 0.070 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 489 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12242 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19862 | 0.070 |
Why?
|
Africa | 1 | 2008 | 670 | 0.070 |
Why?
|
History, 20th Century | 2 | 2004 | 2739 | 0.070 |
Why?
|
Product Labeling | 1 | 2007 | 79 | 0.070 |
Why?
|
Patient Care Team | 1 | 2018 | 2527 | 0.070 |
Why?
|
Gene Frequency | 1 | 2013 | 3587 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15194 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9274 | 0.070 |
Why?
|
Consensus | 1 | 2015 | 2935 | 0.070 |
Why?
|
Computer User Training | 1 | 2005 | 19 | 0.070 |
Why?
|
Pain Measurement | 1 | 2016 | 3418 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12958 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2013 | 2451 | 0.070 |
Why?
|
Health Status | 1 | 2018 | 4030 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3293 | 0.060 |
Why?
|
Education, Nursing, Continuing | 1 | 2005 | 75 | 0.060 |
Why?
|
Child of Impaired Parents | 1 | 2009 | 455 | 0.060 |
Why?
|
Supreme Court Decisions | 1 | 2006 | 128 | 0.060 |
Why?
|
Afghanistan | 1 | 2004 | 81 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2016 | 5310 | 0.060 |
Why?
|
Iraq | 1 | 2004 | 92 | 0.060 |
Why?
|
Taxes | 1 | 2007 | 221 | 0.060 |
Why?
|
Hospitals, Military | 1 | 2004 | 67 | 0.060 |
Why?
|
Endometriosis | 1 | 2012 | 834 | 0.060 |
Why?
|
Internship and Residency | 1 | 2004 | 5774 | 0.060 |
Why?
|
Device Approval | 1 | 2006 | 163 | 0.060 |
Why?
|
Resuscitation | 1 | 2008 | 657 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10392 | 0.060 |
Why?
|
Organizations | 1 | 2004 | 170 | 0.060 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1712 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2018 | 4440 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20774 | 0.060 |
Why?
|
Resuscitation Orders | 3 | 2011 | 267 | 0.060 |
Why?
|
False Positive Reactions | 1 | 2006 | 981 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 546 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2022 | 62966 | 0.060 |
Why?
|
Vaginal Smears | 1 | 2006 | 511 | 0.060 |
Why?
|
Logistic Models | 3 | 2018 | 13403 | 0.050 |
Why?
|
Hospital Information Systems | 1 | 2005 | 395 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 68 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2014 | 1820 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3151 | 0.050 |
Why?
|
Depression | 2 | 2020 | 7733 | 0.050 |
Why?
|
Homicide | 1 | 2004 | 287 | 0.050 |
Why?
|
Commerce | 1 | 2007 | 591 | 0.050 |
Why?
|
Saliva | 1 | 2006 | 805 | 0.050 |
Why?
|
Health Care Costs | 2 | 2019 | 3203 | 0.050 |
Why?
|
Physician's Role | 1 | 2008 | 942 | 0.050 |
Why?
|
Internationality | 1 | 2007 | 1002 | 0.050 |
Why?
|
Primary Prevention | 1 | 2008 | 1166 | 0.050 |
Why?
|
World Health Organization | 1 | 2007 | 1317 | 0.050 |
Why?
|
China | 1 | 2007 | 2246 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15530 | 0.050 |
Why?
|
Genome, Human | 1 | 2013 | 4420 | 0.050 |
Why?
|
Abortion, Induced | 1 | 2006 | 458 | 0.050 |
Why?
|
Disease Progression | 2 | 2020 | 13256 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2004 | 575 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 59 | 0.040 |
Why?
|
HIV Antibodies | 1 | 2006 | 1320 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17400 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2410 | 0.040 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2021 | 434 | 0.040 |
Why?
|
Genotype | 1 | 2013 | 12946 | 0.040 |
Why?
|
Models, Statistical | 1 | 2013 | 5100 | 0.040 |
Why?
|
History, 21st Century | 1 | 2004 | 1533 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2010 | 13921 | 0.040 |
Why?
|
Biomedical Technology | 1 | 2021 | 221 | 0.040 |
Why?
|
Health Services for the Aged | 1 | 2021 | 269 | 0.040 |
Why?
|
Politics | 1 | 2004 | 790 | 0.040 |
Why?
|
Religion and Psychology | 2 | 2010 | 171 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2019 | 77098 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 261 | 0.040 |
Why?
|
Cost Control | 1 | 2019 | 624 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 780 | 0.040 |
Why?
|
Syndrome | 1 | 2023 | 3248 | 0.040 |
Why?
|
Hospitals | 1 | 2010 | 3937 | 0.040 |
Why?
|
Women's Health | 1 | 2006 | 2034 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2018 | 187 | 0.040 |
Why?
|
Uncertainty | 1 | 2021 | 725 | 0.030 |
Why?
|
Models, Economic | 1 | 2019 | 713 | 0.030 |
Why?
|
Research Design | 2 | 2021 | 5979 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1181 | 0.030 |
Why?
|
Pyridones | 1 | 2019 | 712 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1958 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2186 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10372 | 0.030 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 128 | 0.030 |
Why?
|
Core Binding Factor beta Subunit | 1 | 2013 | 45 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2019 | 921 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20086 | 0.030 |
Why?
|
E1A-Associated p300 Protein | 1 | 2013 | 131 | 0.030 |
Why?
|
Research Personnel | 1 | 2018 | 573 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2013 | 4839 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 318 | 0.030 |
Why?
|
HLA-B Antigens | 1 | 2013 | 353 | 0.030 |
Why?
|
Harm Reduction | 1 | 2013 | 129 | 0.030 |
Why?
|
F-Box Proteins | 1 | 2013 | 197 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4929 | 0.030 |
Why?
|
Social Isolation | 1 | 2015 | 363 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 489 | 0.030 |
Why?
|
Virus Integration | 1 | 2013 | 297 | 0.030 |
Why?
|
Risk Factors | 3 | 2013 | 72145 | 0.030 |
Why?
|
Health Education | 1 | 2018 | 1053 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2013 | 364 | 0.020 |
Why?
|
Marital Status | 1 | 2012 | 437 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14720 | 0.020 |
Why?
|
Databases, Factual | 2 | 2016 | 7716 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2502 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3548 | 0.020 |
Why?
|
Focus Groups | 1 | 2014 | 1320 | 0.020 |
Why?
|
Life Support Care | 1 | 2011 | 228 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 3915 | 0.020 |
Why?
|
Sex Offenses | 1 | 2013 | 352 | 0.020 |
Why?
|
Decision Making | 2 | 2013 | 3869 | 0.020 |
Why?
|
Social Stigma | 1 | 2015 | 698 | 0.020 |
Why?
|
Family Characteristics | 1 | 2013 | 999 | 0.020 |
Why?
|
Pain | 1 | 2023 | 4961 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2013 | 622 | 0.020 |
Why?
|
Patient Transfer | 1 | 2014 | 760 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39004 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2014 | 1048 | 0.020 |
Why?
|
Administration, Oral | 1 | 2015 | 3913 | 0.020 |
Why?
|
Sex Distribution | 1 | 2012 | 2295 | 0.020 |
Why?
|
Child | 3 | 2013 | 77478 | 0.020 |
Why?
|
Age Distribution | 1 | 2012 | 2900 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3507 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2790 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5163 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 1940 | 0.020 |
Why?
|
Social Support | 1 | 2015 | 2117 | 0.020 |
Why?
|
Pregnancy | 1 | 2006 | 29087 | 0.020 |
Why?
|
Quality Improvement | 1 | 2019 | 3738 | 0.020 |
Why?
|
Educational Status | 1 | 2012 | 2533 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2013 | 1860 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2011 | 2536 | 0.010 |
Why?
|
Probability | 1 | 2009 | 2502 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2948 | 0.010 |
Why?
|
Home Care Services | 1 | 2009 | 602 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8328 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4553 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13853 | 0.010 |
Why?
|
Boston | 1 | 2012 | 9305 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12695 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20928 | 0.010 |
Why?
|
Genomics | 1 | 2013 | 5692 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8425 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 7901 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7770 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9846 | 0.010 |
Why?
|
Critical Illness | 1 | 2009 | 2665 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9639 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2018 | 15244 | 0.010 |
Why?
|
Signal Transduction | 1 | 2019 | 23387 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21719 | 0.010 |
Why?
|
Transcription Factors | 1 | 2013 | 12164 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15056 | 0.010 |
Why?
|
Risk Assessment | 1 | 2009 | 23320 | 0.000 |
Why?
|
Child, Preschool | 1 | 2009 | 40955 | 0.000 |
Why?
|